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Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
characterized by the degeneration of motor neurons. Though many molecular and
genetic causes are thought to serve as predisposing or disease propagating factors, the
underlying pathogenesis of the disease is not known. Recent discoveries have demonstrated the presence of inflammation propagating substrates in the central nervous
system of patients afflicted with ALS. Over the past decade, this hypothesis has incited
an effort to better understand the role of the immune system in ALS and has led to the
trial of several potential immune-modulating therapies. Here, we briefly review advances
in the role of such therapies. The clinical trials discussed here are currently ongoing or
have been concluded at the time of writing.
Keywords: amyotrophic lateral sclerosis, immunotherapy, microglial activation, neuroinflammation, SOD1

INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the
dysfunction and loss of motor neurons in the brain and/or spinal cord. The striking clinical heterogeneity seen in ALS implies that a single molecular mechanism is unlikely to be responsible for the
onset of the disease. The underlying pathophysiology of ALS is not well understood or characterized
to date. The presence of pro-inflammatory markers in those demonstrating symptoms has been
recognized but the optimal way to modulate this cause of (and response to) neuronal injury remains
to be established.
In ALS, cardinal disruptors of cellular homeostasis were originally thought to be oxidative stress
and glutamate-mediated excitotoxicity. More recently, additional pathogenic processes have been
identified involving protein (metabolism, misfolding, and aggregation), RNA (altered binding), the
endoplasmic reticulum and vesicular transport (1, 2). It has also become evident that inflammation
plays a crucial role in mediating neuronal injury and disease progression (3, 4). Thus, targeting the
immune system would appear to be a more tractable means of slowing the clinical progression of
the disease.
Here, we present a brief overview of inflammation in the central nervous system (CNS) as
relevant to ALS, particularly microglial homeostasis (5). We then summarize clinical trials to date
of immunomodulatory agents based on these recent insights.
The best-studied animal model of ALS replicates a mutation found in familial ALS (fALS),
superoxide dismutase 1 (SOD1). However, only 10–15% of ALS is familial and SOD1 mutations
account for just 10–12% of fALS, thus just 1–2% of all ALS in humans (6).
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Pro- and Anti-inflammatory Immune
Phenotypes in ALS

The most common genetic cause of fALS has been identified as a six-nucleotide repeat expansion in the C9orf72 gene
(chromosome 9, open-reading frame 72). No single abnormality
appears to occur with similar frequency in sALS.
Amyotrophic lateral sclerosis and frontotemporal dementia
(FTD) are now often said to be the ends of spectrum, pathologically (7). In the case of ALS-FTD (ALS with FTD), the C9orf72
expansion appears to account for approximately 40% of familial
and 5–10% of sporadic cases (8). This appears to have important
effects on microglia, discussed below.

Both microglia (M) and T-cells appear to have central roles in
the pathogenesis of ALS. As in other organs, once activated in
response to injury or antigen, microglia and helper T-cells (Th)
differentiate into a pro-inflammatory (classical, M1 and Th1) phenotype. Once the inciting event has been dealt with, these cells
transition to an anti-inflammatory phenotype (‘alternative’, M2
and Th2). This process appears best suited to acute injury; when
the pathogenic stimulus cannot be adequately cleared, chronic
inflammation develops with persistent M1, Th1 activity that can
cause unintended injury to local tissues.
A crucial element in ‘tipping the balance’ from one state to the
other, particularly evident in microglia, is the relative activity of
NOS2 (inducible nitric oxide synthase) vs. ARG1 (arginase 1);
this is shown in Figure 1. This balance is particularly important
for microglia, but is also used by other elements of the immune
system, including T-cells. The expression of NOS2 is increased by
transcription factor nuclear factor kappa B (NF-κB), expression
of which is increased by binding of tumor necrosis factor alpha
(TNFA) to TNF receptor superfamily member 1A (TNFRSF1A).
TNFA can also have antiapoptotic effects and lead to an increase
in neurotrophic factors via TNFRSF1B (discussed further below).

IMMUNE SYSTEM IN ALS
For much of the twentieth century the CNS was thought to be
‘immune privileged’ i.e. protected from invasion from inflammatory cells. Activity of the immune system within the CNS is now
widely accepted.
A lymphatic system lines the dural sinuses and carries
immune cells and fluid to cervical lymph nodes (9). Microglia,
closely related to the macrophages found in other organs, reside
in the CNS. These cells are capable of screening the entire nervous
system for foreign material every few hours (10). While circulating lymphocytes do not pass through an intact blood–brain
barrier (BBB), extravasation does occur during periods of inflammation (11). In the discussion below, we refer to proteins with
their official NCBI names (followed by more common/historical
nomenclature) (12).

Microglia

Like macrophages, microglia become activated via the receptor
complex CD14 + toll-like receptor 4 (TLR4) in response to

Figure 1 | Simplified schema of inflammation in amyotrophic lateral sclerosis (ALS). Some of the treatments in this review with relatively ‘specific’ modes of action
are also shown.

Frontiers in Neurology | www.frontiersin.org

2

September 2017 | Volume 8 | Article 486

Khalid et al.

Immunotherapy for ALS

antigens such as lipopolysaccharide, proteins released from damaged cells (including SOD1protein aggregates, beta-amyloid and
alpha-synuclein), to infiltrative lymphocytes and to signals from
the humoral (i.e. antibody-mediated) immune system (Figure 2).
Relative to the macrophages of other tissues, microglia are less
potent activators of the immune system. This is in part due to
their lower expression of protein tyrosine phosphatase, receptor
type C (aka CD45), leukocyte common antigen and the major
histocompatibility complex (MHC) (13, 14).
The M1 phenotype shows increased expression of pro-inflammatory cytokines such as nitric oxide species, TNFA, and the
interleukins (IL) 1B, IL2, and IL6 (4). Receptors and transmembrane proteins involved in antigen presentation are upregulated,
including MHC class II, CD86 (B7-2, CTLA-4 counter-receptor
B7.2), and the Fc fragment of IgG receptor III (FCGR3; CD16)
(15). They also increase production of reactive oxygen species
(ROS), which are cytotoxic.
M2 microglia secrete anti-inflammatory cytokines such as
IL4, IL10, IL13, TGFB and ARG1 as well as neurotrophic factors
such as glial cell line-derived neurotrophic factor, brain-derived
neurotrophic factor (BDNF), and insulin-like growth factor-1
(IGF1). IGF1 has the capacity to promote growth and differentiation of ‘neural stem cells’, helping with tissue repair (16, 17).
Repair is also mediated via angiogenesis and by remodeling of
the extracellular matrix (18).
Thus, neurodegeneration is facilitated by the lack of neurotrophic growth factors and by the continued production of
cytotoxic byproducts of a pro-inflammatory response.

One factor favoring the inflammatory phenotype (and contributing to neuronal vulnerability to inflammation) is the C9orf72
expansion. This is in a region which functions as an untranslated
promoter in microglia, but is translated by neurons. Under normal circumstances, the highest expression levels in the brain are
found in microglia. With the expansion, production of C9orf 72
is impaired in microglia, resulting in impairment of endosome/
lysosomal trafficking. When attempting phagocytosis, such cells
show an increase in ROS and inflammatory cytokines, thought to
be due to impairment of phagosome/lysosome fusion (19). In neurons, the transcribed C9orf72 RNA and the translation of useless
dipeptides from the expanded repeat both appear to contribute
to susceptibility to inflammation and thus degeneration (8).

Helper T-Cells

Th1 cells secrete pro-inflammatory cytokines such as interferon
gamma (IFNG), IL2 and TNFB (beta); these proteins also promote the M1 phenotype of nearby microglia/macrophages. Th2,
like M2 cells, secrete the anti-inflammatory cytokines IL4 and
IL10; these cytokines also promote the differentiation of microglia/macrophages along M2 lines.
The balance between Th1 and Th2 is influenced heavily by
regulatory T-cells (Treg). These are marked by CD4 and IL2RA
(IL2 receptor subunit alpha, CD25). Their development and
maintenance depend on the transcription factor forkhead box P3
(FOXP3); so-named as mutations in Drosophila cause development of head-like structures at each pole instead of the usual fore/
hind-gut.

Figure 2 | Triggering of inflammation and the role of inflammation in propagating amyotrophic lateral sclerosis.
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Table 1 | Trials of immune-modulating treatments in ALS registered with NCT.
NCT ID

SD

Agent

ra

n

wks

P

RCT

Outcomes
Primary

Secondary

C

R

Rheumatoid arthritis
01277315
2/11 Anakinra
02588677
4/13 Masitinib + riluzole
02469896
11/15 Tocilizumab

po
po
iv

18
394
24

4
48
16

2
2/3
2

N
Y
Y

S/T
ALSFRS-R
S/T

S/T
VC, QoL
ALSFRS-R, VC

Y
Y
N

(26)
NA
NA

Multiple sclerosis
00326625
7/06
01786174
8/13
02238626
8/14
02525471
10/15

Glatiramer acetate
Fingolimod
Ibudilast
RNS60 (saline)

sc
po
po
iv

366
30
120
18

52
8
26
24

2
2
1b/2a
1

Y
Y
Y
N

ALSFRS-R
ALSFRS-R, VC, FEV1
S/T, ALSFRS-R
S/T

ttDV
T-cell subsets
VC, MMT, HHD
ALSFRS-R, VC, HHD

Y
Y
N
N

(38)
(47)
(51)
NA

Anti-inflammatory
00355576
7/06

Celecoxib + creatine

po

86

26

2

N

ALSFRS-R

VC, QoL, TGUG

Y

(59)

‘ALS-specific’
01753076
12/12
01091142
7/10
01281631
2/11
02794857
8/16

Ozanezumab
NP001 (chlorite)
NP001
NP001

iv
iv
iv
iv

304
32
136
120

48
26
39
26

2
1
2
2

Y
N
Y
Y

ALSFRS-R, OS
S/T
ALSFRS-R
ALSFRS-R

VC, HHD, QoL
Biomarkers
VC, TTT, serum IM
TTT, serum IM

Y
Y
Y
N

(63)
(66)
(67)
NA

po
po
sc

18
60
40

39
42
52

2
2
2

N
N
Y

ALSFRS
ALSFRS-R
ALSFRS

S/T, QoL, serum IM
VC, TTT, HHD, ATLIS
AARS

Y
Y
Y

(69)
(73)
(75)

sc
sa

40
14

13
12

2/3
1/2

Y
N

ALSFRS-R
S

Y
Y

(76)
NA

im

20

104

1

N

S

CMAP, MMT, ALSAQ-40
Functional independence,
balance, dysarthria
MUNE, CMAP, MRC

N

NA

iv,
po

33

52

2

N

ALSFRS-R

VC, HHD, serum IM, CSF IM

Y

NA

Treatment of cancer
00140452
2/05 Thalidomide
01257581
3/11 Tamoxifen
00397423
12/06 Granulocyte colony-stimulating factor
(G-CSF)
01825551
11/12 G-CSF
03085706
10/10 Peripheral blood mononuclear cell
autotransplantation
02286011
11/14 Bone-marrow mononuclear cells
Transplant rejection
01884571
10/13 Basiliximab, mycophenolate, tacrolimus,
methylprednisolone, prednisone

ALS, amyotrophic lateral sclerosis; NCT ID, NIH Clinical Trials identifier; SD, start date (month/year); ra, route of administration; po, oral; iv, intravenous; sc, subcutaneous; sa,
subarachnoid space (i.e., into CSF); im, intramuscular; n, number of subjects; wks, duration of trial (weeks); P, Phase (1–3); RCT, randomized, double-blind, placebo-controlled trial?
C, completed? (at time of writing); R, reference; NA, not applicable (no results reported yet).
Outcomes—note not all secondary outcomes are listed, for reasons of space.
S, safety; T, tolerability; ALSFRS-R, ALS Functional Rating Scale (revised); VC, vital capacity (any method); FEV1, forced expiratory volume in 1 sec; OS, overall survival; QoL, quality
of life; ttDV, time to death or ventillator-dependence; MMT, manual muscle testing; HHD, hand-held dynamometry (muscle strength); TGUG, timed get-up-and-go (sitting to walking);
TTT, time to tracheostomy; IM, inflammatory markers; ATLIS, accurate test of limb isometric strength; AARS, Appel ALS Rating Scale; CMAP, compound muscle action potential;
ALSAQ-40, ALS Assessment Questionnaire-40; MUNE, motor units estimate (number of motor units); MRC, Medical Research Council (score, muscle strength).

Regulatory T-cells encourage M2 differentiation and impede
the activity of cytotoxic T-lymphocytes (Tc, including natural
killer T-cells). Lower circulating levels of Tregs have been shown
in those with ALS vs. controls (20). Lower levels of Tregs and of
FOXP3 have also been correlated with the rate of clinical progression of ALS and may be a useful prognostic biomarker that could
be used to stratify groups in clinical trials (21).

are discussed here which were not registered with NCT. Also,
some NCT-registered trials do not yet have a corresponding
article reporting results and are referenced here with their NCT
identifier.

Measures of Outcome

The most commonly used measure of outcome in these trials is
the change in the ALS Functional Rating Scale (ALSFRS) over
time. In 1999, the scale was revised to include assessments of
dyspnea, orthopnea, and the need for ventilatory support. This
latter, the ALSFRS (revised) (ALSFRS-R) has been adopted by the
majority of clinical investigators since (22). Due to the restrictive
effect of ALS on pulmonary function, forced vital capacity (FVC)
is also often used as a measure of disease progression.

CLINICAL TRIALS
Search Methods

We searched the NIH’s ClinicalTrials.gov (NCT), a database of
medical studies in human volunteers, with the term “amyotrophic
lateral sclerosis” for any trials focused on modifying inflammation. We included trials currently in progress or completed prior
to the time of writing. These trials are summarized in Table 1,
where they appear in the same order as the treatments discussed
below. We classified these treatments based on their use in
other pro-inflammatory diseases. They are sorted (broadly) by
treatment and by the year the trial began accrual. Some trials

Frontiers in Neurology | www.frontiersin.org
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Rheumatoid arthritis (RA) has been noted with a greater frequency than would be expected by chance in the families of those
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affected by ALS (23). In the case of the individual patient, just
seven cases of co-occurring ALS and RA have been reported to
date. It is thought that most if not all cases were the result of a
chance association; indeed the coincidence of the two conditions
would appear to be less than might be expected by chance alone.
Notably, as reported by Padovan et al., in two patients with
RA, ALS developed rapidly after the introduction of or increase in
dose of infliximab, a TNFA antagonist (24). While these authors
acknowledge the limitations of such anecdotal observations,
this finding would fit with an upregulation of the antiapoptotic
TNFRSF1B in chronic RA, thereby masking a tendency toward
ALS in the cases they report. Another case in support of this
mechanism is that of a patient with psoriatic arthritis who developed ALS rapidly after starting adalimumab, another antibody
targeting TNFA (25).

psoriasis as well as patients with sALS. Using peripheral blood
mononuclear cells (PBMCs i.e. T and B cells as well as monocytes) from four patients with sALS, tocilizumab was shown to
inhibit the pro-inflammatory effects of adding mutant SOD1G93A (31). In particular, the expression of a number of cytokines
was reduced in vitro: IL6, IL1B, TNFA, IFNG and GM-CSF. A
Phase 2 RDBPCT investigating the safety and tolerability in adult
patients with ALS is ongoing. In addition to safety measures, the
study investigates the effect of tocilizumab on novel biomarkers
including PBMC gene expression profiles and MRI-PET imaging
of activated microglia.

DRUGS USED FOR MULTIPLE
SCLEROSIS (MS)
Like RA and ALS, MS and ALS appear to aggregate within
families, while co-occurrence in one individual appears rare. We
are aware of just four such case reports to date (32). Microglial
activation appears partly responsible for neuronal injury in both
ALS and MS (33).

Anakinra

Interleukin 1 is an endogenous pyrogen and a mediator of autoimmune and infectious diseases (26). Anakinra, a recombinant
analog of the endogenous antagonist IL1Ra, has already proven
effective in the treatment of refractory RA (27). IL1R antagonists
have been shown to extend lifespan in SOD1-G93A mice (28).
A pilot study of 17 patients treated with anakinra (at the same
dose used for RA, 100 mg daily) for 1 year showed no significant
reduction in disease progression, measured with the ALSFRS-R.
Though the study did show a decrease in cytokines and fibrinogen
during the initial 24 weeks of treatment, there was a ‘rebound’
increase in inflammatory markers during the latter half of the
study (29).

Glatiramer Acetate (GA)

Glatiramer acetate is comprised of random polymers of glutamic
acid (G), lysine (L), alanine (A), and tyrosine (T). It has long been
used in the treatment of relapsing–remitting MS. In such patients,
treatment with GA leads to an increase in IL10 and IL4 and a
decrease in TNFA (34). GA may also increase Treg activity.
The safety of GA in ALS has been demonstrated in a Phase
1 trial of 20 patients and 10 controls, with doses of 20 mg given
daily or biweekly to 10 patients each. GA appeared safe and
encouraging immunological changes were measured (35).
A Phase 2 RDBPCT with 366 patients used GA 40 mg/day
(vs. ×3/week, as is typical in MS). They remained under observation for 52 weeks. No significant difference in the rate of deterioration (ALSFRS-R) or overall survival was seen (36). The authors
speculate that differences in BBB permeability between MS and
ALS (affecting the pharmacokinetics of GA or the traffic of the
immune system into the CNS) may account for these results.

Masitinib

Masitinib is a pluripotent tyrosine kinase inhibitor which affects
multiple pro-inflammatory mast cell receptors. It inhibits mast cell
degranulation and mobility. Studies of masitinib in RA, systemic
mastocytosis, mast cell tumors and in Alzheimer’s disease have
already shown promising results. In SOD1-G93A rats, masitinib
was shown to decrease microglial cell activation via inhibition
of colony-stimulating factor 1 receptor (30). Masitinib may also
prevent macrophage infiltration into the ventral root by inhibiting KIT (KIT proto-oncogene receptor tyrosine kinase), thereby
delaying the ‘dying back’ phenomenon associated with anterior
horn cell dysfunction (unpublished data, Emilianos Trias et al.).
A Phase 3 randomized, double-blind, placebo-controlled trial
(RDBPCT) is ongoing to determine the efficacy of riluzole plus
masitinib vs. placebo in ALS over the course of 48 weeks. The
interim results are encouraging, with 50% (191 of 381) of patients
having completed the riluzole and masitinib arm. A statistically
significant difference was seen in the ALSFRS-R score as well as
the secondary end points: change in the Combined Assessment
of Function scale and FVC.

Fingolimod

Fingolimod is an inhibitor of the sphingosine 1-phosphate
receptor (S1PR). This receptor is found on immune cells,
neural cells, endothelial cells and smooth muscle. It is thought
to play a role in angiogenesis, neurogenesis and immune
regulation/trafficking. Inhibition of S1PR causes sequestration
of lymphocytes within lymph nodes, thereby reducing their
numbers in the blood stream. It has already proved to be effective in MS (37).
In SOD1-G93A mice, fingolimod improved survival. Its
immunomodulatory effects are mediated through NOS2, IL1B,
FOXP3, IL10, ARG1, integrin subunit alpha M (CD11B, part of
complement receptor 3) and BDNF (38). An RBDPCT, with 2:1
randomization, in 30 patients with ALS showed the treatment to
be safe and tolerable (one patient stopped treatment due to QT
prolongation) (39). We are not aware of plans to study this agent
further in ALS.

Tocilizumab

Interleukin 6 signaling is major inducer of the acute-phase
response; its receptor is blocked by the monoclonal antibody
tocilizumab. Increased serum IL6 is recognized in autoimmune
diseases such as RA, systemic-onset juvenile chronic arthritis and

Frontiers in Neurology | www.frontiersin.org
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Ibudilast

the prostaglandin-induced release of glutamate. One RDBPCT
enrolled 30 patients with ALS and randomized their treatment
(2:1) between celecoxib and placebo for 12 months. No difference was found in disease progression (ALSFRS-R), muscle
strength (maximum MVIC), FCV, or in estimates of numbers
of motor units (49).
Celecoxib has also been evaluated in a Phase 2 adaptive trial.
Here, it was compared with minocycline; both were given with
creatine in order to aid mitochondrial function (50). Historical
controls were used as a comparison. Planned enrollment was with
sequential pools of 60 patients per arm; after one pool per arm,
the celecoxib–creatine regimen proved superior to that of minocycline–creatine, although not greatly superior to the historical
controls, as assessed by the rate of decline in the ALSFRS-R at
6 months (35).

Ibudilast is a an inhibitor of TLR4 and phosphodiesterase 3 and
4 which has shown immunomodulatory effects in MS by shifting the immune response from Th1 to Th2 (40). In ALS, TLR4
facilitates the transformation of M2 to M1 microglia (41). The
safety profile of ibudilast has been established through long use
in the treatment of asthma in Japan. It has been shown to reduce
the loss of brain volume change in patients with MS (42). A Phase
2 trial of safety and efficacy in patients with ALS has completed
accrual and preliminary reports on safety and tolerability are
encouraging (43).

RNS60

RNS60 is modified saline; it is mixed with oxygen in a controlled
manner to generate stable, electrically charged nanobubbles.
This agent is undergoing clinical trials in MS as well as ALS.
The electrical charge carried by RNS60 affects membrane ion
channels and increases mitochondrial ATP production in cell
culture (44, 45). In a mouse model of MS, it has been shown to
reduce NO and NOS2 production and thus is anti-inflammatory
(46). This effect is thought to be mediated through the inhibition
of NF-κB (47). This results in ‘tipping the balance’ toward the
alternative (M2, Th2) response.
As the drug’s effects are a result of biological and not chemical
activity, preclinical toxicology studies have shown almost no side
effects. Safety has been established in three Phase 1 studies, one
intravenous and two using inhalation. A Phase 1 trial of intravenous RNS60 has completed patient accrual (NCT02525471). This
will investigate its efficacy as measured by the ALSFRS-R and on
inflammatory biomarkers.

AGENTS ‘SPECIFIC’ TO ALS
Ozanezumab

‘NON-SPECIFIC’ ANTI-INFLAMMATORY
AGENTS

Activation of the reticulon 4 receptor (RTN4R, aka Nogo receptor) inhibits the growth of axons in mammals following peripheral nervous system injury. RTN4R is also found on macrophages,
where, following Wallerian degeneration, it has been shown to
mediate the clearance of these cells from the site of injury (51).
Additionally, RNT4 (Nogo-A) is overexpressed in the skeletal
muscle of patients with ALS (52).
Thus, ozanezumab (an antibody targeting RNT4) may help
slow disease progression, either by decreasing the inhibition of
axonal growth or by affecting the inflammatory process following
neuronal injury. An RDBPCT with 303 patients tested this treatment, given over 48 weeks. No difference in disease progression
(ALSFRS-R) or in survival was seen (53). The results are not
thought to have been due to inadequate dosing or pharmacokinetic factors.

Intravenous Immunoglobulin (ivIg)

NP001

Two small ‘pilot’ studies to assess the effects of a 3-month course
of ivIg on the severity of ALS have proved disappointing; this
appears to have put an end to investigation of this modality.
These studies were performed prior to the advent of the ALSFRS;
instead, participants served as their own controls.
The first in nine patients with ALS used ivIg 2 g/kg monthly
for 3 months. No change in disease severity was seen using the
outcome measure of maximum voluntary isometric contraction
(MVIC), as per the Tufts Quantitative Neuromuscular Evaluation
system (48). A subsequent study used the same dose and timing
in combination with cyclophosphamide 1–2 mg/kg/day in seven
patients over 4–13 months. The rate of deterioration was no
slower after starting treatment than before, as measured by the
means of the Medical Research Council (MRC) score for muscle
strength (10 muscles/limb = 40 muscles), a clinical scale for
bulbar function (range 1–5) and the modified Rankin disability
scale (range 0–5).

Taurine is an amino acid not incorporated into protein, which
binds HOCl, as produced by the oxidative burst of activated
neutrophils. The product of this reaction, taurine chloramine,
is a less toxic oxidizing agent than HOCl; it is also a signaling
molecule that contributes to the self-limiting nature of inflammation. Sodium chlorite (NaClO2; in solution with 63 mM chlorite
and pH-corrected = NP001, aka WF10) was developed to mimic
this effect. In PBMCs stimulated by anti-CD3 (part of the T-cell
receptor complex), WF10 reduced IL2 production as well as the
nuclear translocation of the transcription factor nuclear factor of
activated T-cells 1 (NFATC1).
WF10/NP001 was originally developed for advanced-stage
HIV, to suppress the chronic activation of macrophages, which
is thought to be partially responsible for neurological injuries
in HIV (54, 55). It is also being investigated as a treatment for
MS, although work in ALS is farther along than in these other
conditions.
A Phase 1 trial in 32 patients showed the treatment to be safe
and well tolerated (56). There was a dose-dependent decrease in a
marker of monocyte activation, FCGR3. A subsequent RDBPCT
with 136 patients showed no effect on ALSFRS-R, although a

Celecoxib

Celecoxib, a cyclooxygenase-2 inhibitor (prostaglandin G/H
synthase) is used to treat pain and inflammation; it also decreases
Frontiers in Neurology | www.frontiersin.org
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An RDBPCT in 10 patients used a dose of 10 μg/kg on days
1–10 and 20–25 (64). No difference in disease progression at
100 days (ALSFRS) was noted. There was a smaller decline in
fractional anisotropy of the brain in the treated group. This MRI
finding, which measures the ‘directionality’ of water flow, is
considered a marker of axonal myelination (65).
Based on these encouraging results, a larger RDBPCT was
performed with 40 patients, using G-CSF at 5 μg/kg/q12h for
5 days; they were observed for 3 months. There was no change
in disease progression, as measured with the ALSFRS-R, the
ALS Assessment Questionnaire-40, manual muscle testing, and
CMAPs (66). Although the duration of the trial was relatively
short, the authors note “previous studies suggest that a longer
duration of follow-up is unlikely to confer any important clinical
benefit with currently administered doses of G-CSF.” The small
sample size was based on a large expected difference in the
change in ALSFRS-R, which may in retrospect have been a
little optimistic. Another trial of G-CSF in 40 patients appears
to have been completed, although no results are available
(NCT00397423).

subset of those with high baseline serum inflammatory markers
(including IL6, IFNG and CRP) did show stabilization of disease
(57). A follow-up, focused on those with ALS and high baseline
CRP, is ongoing.

TREATMENTS USED PRIMARILY
IN PATIENTS WITH CANCER
Thalidomide

Thalidomide is an immunomodulating agent whose effects on
TNFA have been shown to be beneficial in SOD1-G93A mice
(58). A trial using 400 mg/day, with outcomes available in 18
patients, showed no improvement in ALSFRS or FCV vs. historical
controls. (This dose is similar to that used for refractory chronic
graft-versus-host disease and to that used in the multi-agent
treatment of multiple myeloma.) Treatment with thalidomide
was associated with a number of adverse effects, including deep
vein thrombosis and bradycardia (59). Bradycardia appears common, with another study reporting a rate of 50% in 18 patients,
when used in combination with riluzole (60).

White Blood Cell Support

Tamoxifen

Isolation of mononuclear cells from blood and bone marrow
has long been used to provide support for patients undergoing
myelotoxic chemotherapy or marrow transplantation. Thus,
such facilities are likely to be available wherever such treatments
are used.
A single-center, Phase 1 RDBPCT to assess the rate of adverse
events related to the intramuscular infusion of autologous
mononuclear cells of bone marrow is currently underway and
scheduled to complete at the end of 2017 (NCT02286011). A
similar study was completed to access the deliverance of PBMC
transplantation into the subarachnoid space, but has not yet
reported results (NCT03085706).
Another Phase 1 trial with three patients used leukapheresis
followed by isolation and expansion of Tregs. They received four
infusions of these Tregs every 2 weeks, with simultaneous subcutaneous IL2 (to expand T-cells). This modality appears safe and
clinical benefits were noted for up to 1 month after the infusions
were stopped (67).

A competitive inhibitor of estrogen receptors, tamoxifen
continues to be used as adjuvant treatment for breast cancer
as well as endometrial carcinoma. Slowing of ALS progression
was reported in a woman who started tamoxifen treatment for
breast cancer at the 2004 International ALS/MND Symposium.
Its anti-inflammatory effect may result from inhibition of protein
kinase C (3). A Phase 2 trial in 60 patients reported an increase in
survival in those using more than 20 mg/day vs. lower doses (61).
Another Phase 2 trial randomized patients to daily creatine
30 mg or tamoxifen 40 vs. 80 mg. In those taking the higher dose
of tamoxifen, disease progression was reduced (ALSFRS-R), an
effect which remained significant after controlling for gender, site
of disease onset and VC. These results were presented by Atassi
et al. at the Northeast ALS Consortium Webinar 2013.1

Granulocyte Colony-Stimulating Factor
(G-CSF, Filgrastim)

This compound stimulates the proliferation and differentiation
of granulocytes; it has been shown to play a part in neuro- and
angio-genesis as well as modulation of the immune system. It
is commonly used in myelotoxic chemotherapy to prevent or
treat neutropenia. In SOD1-G93A mice, use of pegylated G-CSF
increased survival and reduced microgliosis (62).
A pilot study, with 10 patients available for complete assessment, used a dose of 2 g/kg for 5 days. While the first 3 months of
showed a significant reduction in the rate of decline (ALSFRS),
there was a ‘rebound’ worsening in the subsequent 3 months (63).
The decline in compound muscle action potential (CMAP) was
also reduced during the first 3 months and remained unchanged
thereafter.

1

TREATMENTS USED AS PART OF ORGAN
TRANSPLANTATION
Cyclosporine

Cyclosporine, which reduces production of IL2, is an oral
agent which does not appear to cross the intact BBB. When
infused into the lateral cerebral ventricle of SOD1-G93A mice,
cyclosporine leads to improved survival (68). An RDBPCT of 74
patients used variable dosing to achieve a target serum level of
400–600 ng/mL. This level is slightly higher than that typically
used after solid organ transplant (100–400 ng/mL). A slower
rate of progression was seen in men who started to receive treatment within 18 months of symptom onset. However, those who
entered the study later in the disease course than 18 months
showed no improvement (69).

http://vimeo.com/66738855.
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relapse and disability, patients were willing to accept a risk of
approximately 1% for each of progressive multifocal leukoencephalopathy, leukemia and liver failure (74). Similar patient
risk/benefit preferences have not been studied for ALS. Such
work will likely need to wait for robust estimates for a treatment
with proven efficacy.
The immune-suppressing treatment with the greatest potential short-term risk and arguably the greatest prospect of longterm control remains autologous bone marrow transplantation
(ABMT). Preliminary experience of safety and efficacy in MS has
proved encouraging, with transplant-related mortality rates of
0.3% (349 patients transplanted after 2005) and 0% (119 patients
treated with a low-intensity regimen) (75). ABMT is not under
investigation in ALS, to our knowledge.
Many of the drugs discussed above have also proved effective
in psoriasis, a common inflammatory condition that also injures
ectoderm-derived cells and is characterized by a chronic Th1
response, but that has received almost no attention in relation to
ALS. While psoriasis tends to develop at a far younger age, any
association (or lack thereof) in an individual or family affected
by ALS could improve our understanding of both conditions. Of
course, affecting inflammation within the relatively ‘immuneprivileged’ CNS (vs. skin) has proved to be more challenging,
in part due to accessibility and differences in pharmacokinetics.
The problem in translating work in mice into trials in humans
in ALS is well recognized and has been reviewed by Mitsumoto
et al. (5). SOD1-G93A remains the predominant mouse model.
Given the rarity of SOD1-G93A as a cause of fLAS, trials conducted in those affected have proved difficult to perform and
arguably would be limited relevance to sALS. Importantly, this
mouse model has a different cause than sALS; the latter appears
to have a variety of predisposing and precipitating factors, all
of which converge on motor neuron death. This phenomenon,
whereby a variety of pathological processes converge on a common phenotype, is also seen in Parkinson’s and (arguably) in
Alzheimer’s disease. In both conditions, a subtype characterized
by inflammation (vs. other metabolic abnormalities) has been
proposed (76, 77). Splitting or stratifying such ‘hot’ vs. ‘cold’
disease subtypes appears to be a rational strategy, particularly
while investigating anti-inflammatory and immune-suppressing
treatments.
Focusing on the mediators of disease progression (vs. inciting
mechanisms), particularly the immune system, thus offers the
promise of treatments which are applicable to a wide range of
patients with ALS.
Despite these challenges and the number of negative results,
work by trialists has done much to improve our understanding
of ALS in untreated patients. The ALS Patient Care Database
should also prove valuable in this regard (78).
Whether ALS may be said to have a ‘natural history’ is debatable, as continuous improvements in supportive care have led to
better outcomes for those affected. This is particularly true in
the case of preventing infections, pressure ulcers, malnutrition
(with feeding via gastrostomy if necessary) and respiratory
failure (with non-invasive ventilation). Bearing this in mind,
we hope that a ‘pooled’ cohort of patients receiving placebo as
part of a clinical trial will become available. Such patients could

Irradiating the thymus, spleen and lymph nodes (while shielding non-lymphoid organs) is a treatment used typically in
preparation for organ transplant and occasionally for severe
cases of autoimmune diseases such as RA. One RDBPCT with
61 patients showed no difference, after 2 years observation, in
muscle strength (via MRC or dynamometer), swallowing (time
to swallow 4 oz water), walking (time to walk 15 and 25 feet) or
survival (70).

Prevention of Transplant Rejection

A variety of agents, typically in combination, are used to prevent acute graft-versus-host disease in transplant recipients.
An observation in ALS patients undergoing neural stem cell
injections into the spinal cord lead to the hypothesis that the
immune-suppression required for the injections was, at least in
part, responsible for the therapeutic effects. A Phase 2 trial with
33 patients to assess this has been completed (NCT01884571).
This used basiliximab (anti-IL2) with mycophenolate (an inhibitor of nucleotide synthesis, which T- and B-cells rely upon) and
tacrolimus (inhibits translocation of NFATC1 and thus transcription of IL2, TNFA, IFNG and NOS2 among other effects) as well
as steroids.

DISCUSSION
The majority of the agents we reviewed appear safe and well
tolerated; many are already in use for other conditions and so
good information is available regarding side effects and monitoring. The most promising approaches identified in our review
included NP001, masitinib–riluzole, celecoxib–creatine and
tamoxifen–creatine [(58, 66, 71), NCT02588677]. All of these
treatments await confirmation in larger RCTs.
As ALS progresses, so does the risk of infection, particularly
aspiration pneumonia. Also, the part played by ‘tractable/
modifiable inflammation’ relative to ‘degeneration’, as a cause
of clinical disability, is likely to decrease, although this requires
further investigation. In the case of secondary-progressive MS,
where this transition has been better studied, CNS inflammation
does not appear to cease, but becomes more difficult to address
as much of the inflammation it is ‘hidden’ behind the BBB (72).
Thus, the risk/benefit ratio to immunosuppression in ALS
is likely to increase with disease progression. A number of the
treatments above are strongly immune-suppressing and the risk
of infection associated with such medicines is well recognized
in treating other autoimmune disorders, particularly in rheumatology (71). The risk of cancer with long-term immunosuppression in the setting of solid organ transplant has also been
acknowledged. With a follow-up of 15 years after transplant, the
sex- and age-standardized incidence ratio (i.e., number of cancers observed/number of cancers expected) has been estimated
at 2.2 (73).
In other inflammatory conditions with progressive disability,
patients appear willing to accept an early risk of complications
in return for preventing later disability. In the case of a survey
of MS patients, in return for approximately 5 years free of
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CONCLUSION
A number of basic science and clinical research studies have
demonstrated a correlation between the immune system and
ALS pathology. Despite these findings, the optimal targets have
yet to be elucidated. It remains to be seen if inflammation is of
similar importance in all forms of ALS. Improving our knowledge
of inflammatory biomarkers that correlate with ALS progression may speed the development of such immune-modulating
treatments.
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